The Use of CoSeal (Sealant Agent) in Patients During Left Ventricular Assist Device Surgery

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

4 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-06-30

Study Completion Date

2014-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the use of a device called CoSeal™. CoSeal™ is an FDA approved synthetic (man-made) surgical sealant which is currently used to help stop leaks in blood vessels during surgery.

This study is evaluating CoSeal™ when it is applied to various areas of the heart during the surgery to implant a Left Ventricular Assist Device (LVAD). the investigators are looking for evidence which indicates that CoSeal™ may be useful in reducing or stopping bleeding, the occurrence of micro emboli (small particles of air or blood), and the formation of cardiac adhesions (scar tissue strands that may form around the heart in the area of a previous LVAD operation) in patients who undergo LVAD implantation surgery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Clinical Characteristics, Management and Prognosis of Patients Developing Intraoperative Cardiac Arrest During Transcatheter Aortic Valve Implantation

NCT04687202

Cardiac Arrest, Transcatheter Aortic Valve Implantation

UNKNOWN

Administration of AdVEGF-All6A+ to Myocardium of Individuals With Diffuse CAD Via Minimally Invasive Surgery

NCT01757223

Coronary Artery Disease

WITHDRAWN PHASE1/PHASE2

Bioabsorbable Occluder for Outlet VSD: Safety and Aortic Valve Effects

NCT07040579

Congenital Heart Defects VSD

NOT_YET_RECRUITING

Safety and Feasibility of the Transcatheter Tricuspid Valve Repair System (Trialign)

NCT04936802

Tricuspid Regurgitation

UNKNOWN NA

Minimally Invasive Transthoracic Device Closure in Perimembranous Ventricular Septal Defect

NCT02644330

Perimembranous Ventricular Septal Defect

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, single-blind (subjects and surgeon evaluator are blinded), randomized, multi-center, pilot study which is designed to evaluate the effects of CoSeal™ when used during a surgical procedure to implant a LVAD. The study sample size is 30 subjects; subjects will be randomized in a 2:1 fashion, 20 subjects will be randomized to CoSeal™ in the Treatment Group and 10 subjects will be randomized to no sealant in the Control Group. Bioglue will be used in the control group, only if necessary.

The Primary Objective of this prospective pilot study is to evaluate the use of CoSeal™ for its ability to reduce bleeding following the implantation of a LVAD. The secondary objectives will evaluate the use of CoSeal for its ability to reduce micro emboli during the LVAD implant procedure and prevent tissue adhesions following the implantation of a LVAD.

CoSeal™ (Baxter, Deerfield, Ill., USA) is a synthetic hydrogel consisting of two solutions of high molecular weight of polyethylene glycol which are co-extruded with a liquid sodium phosphate buffer from a syringe housing unit. The device is approved by the FDA for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage and it has been shown to provide superior anastomatic suture line sealing. In 2005, the CoSeal™ medical device was also approved in Europe and Australia for use in patients undergoing cardiac surgery to prevent or reduce the incidence, severity, and extent of post-surgical adhesions.

Data from this study will not be used to support any labeling changes. This is a PI initiative study that was submitted and granted funding from Baxter Healthcare for data and publishing of study data.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Ventricular Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CoSeal Arm

patient randomized to received Coseal during LVAD implantation

Group Type EXPERIMENTAL

CoSeal

Intervention Type DEVICE

3 - 8mls of Coseal

BioGlue® Surgical Adhesive

BioGlue® Surgical Adhesive or use of no sealant application

Group Type PLACEBO_COMPARATOR

BioGlue® Surgical Adhesive

Intervention Type DEVICE

Total amount applied - 8 mls

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CoSeal

3 - 8mls of Coseal

Intervention Type DEVICE

BioGlue® Surgical Adhesive

Total amount applied - 8 mls

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Control - BioGlue® Surgical Adhesive or use of no sealant

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject or the subject's legal representative has signed the IRB approved study informed consent.
* Subject is greater than or equal to 18 years of age.
* Subject has a known indication for implantation of a LVAD and meets the requirements for its implantation.
* Subject who, in the opinion of the investigator, will not require removal of the LVAD earlier than 6 weeks after implantation.

Exclusion Criteria

* Subject requires the concomitant use of any other anti-adhesion product during LVAD implantation.
* Subject has an immune system disorder, immuno-deficiencies, or immuno-suppression.
* Subject has known hypersensitivity to the study device, CoSeal™, or any component of the study device.
* Subject is currently participating in another clinical trial for adhesion prevention or sealing evaluation and/or who has received such an investigational drug or device within the previous 30 days.
* Subject has previously undergone a LVAD implantation/explantation.
* Subject is pregnant or currently breast-feeding.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No